Screening criteria set for Swedish pre-school children needs to change

Article

A Swedish initiative for screening the vision of six-years olds has found that those with a visual acuity (VA) of 0.65 rarely have defects that require treatment, making the current criterion of 0.8 too demanding on the available resources.

A Swedish initiative for screening the vision of six-years olds has found that those with a visual acuity (VA) of 0.65 rarely have defects that require treatment, making the current criterion of 0.8 too demanding on the available resources, according to a report published in the June issue of Acta Ophthalmologica Scandinavia.

Anna-Lena Hård from the Institute of Neuroscience and Physiology at Gothenburg University, Gothenburg, Sweden evaluated the new vision screening methods with particular attention to screening criteria. The current requirements state that, pre-school children with a VA <0.8 or symptoms, should be referred to eye clinics for VA testing, cover testing, cycloplegic autorefraction and ophthalmoscopy. The current screening limit of 0.8 was evaluated in relation to a limit of 0.65.

A total of 3,885 pupils underwent screening. Of these, 225 (6.6%) were referred and 236 underwent ophthalmological examination. Seventy-five percent of these were children with a VA of 0.65 in the worse eye and more than half of these were found, by the clinic, to have a VA of ≥0.8. Only 6.7% were found to have significant ammetropia.

Hård concluded that the current screening and referral criterion of 0.8 is too high, since most children with a VA of 0.65 rarely have defects requiring treatment.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.